Literature DB >> 8131513

Mast cells in fibrotic lung disorders.

A Pesci1, G Bertorelli, M Gabrielli, D Olivieri.   

Abstract

Fibrotic lung disorders are chronic inflammatory diseases in which inflammatory processes in the lower respiratory tract injure the lung and modulate the proliferation of mesenchymal cells that form the basis of the fibrotic scar. The pathogenesis of fibrosis in fibrotic lung disorders remains unclear; however, recent attention has focused on the potential role of the mast cell in the genesis of fibrosis. To determine whether mast cells are implicated in the pathogenesis of lung fibrosis, mast cells were compared with the degree of fibrosis in transbronchial lung biopsy specimens from 49 patients with fibrotic lung disorders (16 sarcoidosis, 15 farmer's lung disease, 9 cryptogenic fibrosing alveolitis, 6 bronchiolitis obliterans organizing pneumonia, 3 histiocytosis X). In lung tissue of patients with fibrotic lung disorders, there was an increased number of mast cells in respect to the control group (98.6 +/- 7.7 vs 27.8 +/- 5.1 mast cells per square millimeter, p < 0.01). Mast cell counts in lung biopsy specimens were significantly correlated with the degree of fibrosis (r = 0.87, p < 0.001); 80.8 percent of mast cells were found in the alveolar septa, 9.6 percent within alveoli, 1.9 percent among alveolar lining cells, and 5 percent along blood vessels. No mast cells were located within alveoli in controls. Our data suggest that mast cells participate in chronic inflammation and that their presence is related to interstitial fibrosis in a much broader spectrum of fibrotic lung disorders.

Entities:  

Mesh:

Year:  1993        PMID: 8131513     DOI: 10.1378/chest.103.4.989

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  26 in total

1.  A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis.

Authors:  Yasmina Bauer; John Tedrow; Simon de Bernard; Magdalena Birker-Robaczewska; Kevin F Gibson; Brenda Juan Guardela; Patrick Hess; Axel Klenk; Kathleen O Lindell; Sylvie Poirey; Bérengère Renault; Markus Rey; Edgar Weber; Oliver Nayler; Naftali Kaminski
Journal:  Am J Respir Cell Mol Biol       Date:  2015-02       Impact factor: 6.914

2.  Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis.

Authors:  K A Boomars; S S Wagenaar; P G Mulder; H van Velzen-Blad; J M van den Bosch
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

Review 3.  Mast cells in airway diseases and interstitial lung disease.

Authors:  Glenn Cruse; Peter Bradding
Journal:  Eur J Pharmacol       Date:  2015-05-08       Impact factor: 4.432

Review 4.  Extracellular superoxide dismutase in pulmonary fibrosis.

Authors:  Fei Gao; Vuokko L Kinnula; Marjukka Myllärniemi; Tim D Oury
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

Review 5.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

Review 6.  Immunomodulatory functions of the diffuse neuroendocrine system: implications for bronchopulmonary dysplasia.

Authors:  Mary E Sunday; Lin Shan; Meera Subramaniam
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

Review 7.  Key role of mast cells and their major secretory products in inflammatory bowel disease.

Authors:  Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

8.  Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase.

Authors:  K C Fang; W W Raymond; S C Lazarus; G H Caughey
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

Review 9.  Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases.

Authors:  Katy M Roach; Peter Bradding
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

10.  PTH promotes allograft integration in a calvarial bone defect.

Authors:  Dmitriy Sheyn; Doron Cohn Yakubovich; Ilan Kallai; Susan Su; Xiaoyu Da; Gadi Pelled; Wafa Tawackoli; Galen Cook-Weins; Edward M Schwarz; Dan Gazit; Zulma Gazit
Journal:  Mol Pharm       Date:  2013-11-08       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.